1 / 13

HTA – for better and worse Florian Berghea , MD. PhD. UMF “ Carol Davila” Bucharest

HTA – for better and worse Florian Berghea , MD. PhD. UMF “ Carol Davila” Bucharest berghea1@gmail.com 6 October 2011. A TRUE STORY…. Michael Drummond – one of the most preeminent voice in HTA. Best crash course in HE. HTA GENERATES UNHAPPY / ANGRY / AGGRESSIVE PEOPLES (UNFORTUNATELY).

Download Presentation

HTA – for better and worse Florian Berghea , MD. PhD. UMF “ Carol Davila” Bucharest

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. HTA – for better and worse Florian Berghea, MD. PhD. UMF “ Carol Davila” Bucharest berghea1@gmail.com 6 October 2011

  2. A TRUE STORY… Michael Drummond – one of the most preeminent voice in HTA Best crash course in HE

  3. HTA GENERATES UNHAPPY / ANGRY / AGGRESSIVE PEOPLES (UNFORTUNATELY)

  4. UNHAPPY / ANGRY / AGGRESSIVE PEOPLES OF HTA What makes them so? Possible solutions?

  5. What makes them so? Possible solutions? HTA process CONCLUSION

  6. Timing of hta • When is the right time for the assessment? • Should we rely on RCT / bioequivalence data or should we wait for real life data? (how about compliance?) • Should we use early data or should we wait for later results? effect Cohort 1 Cohort I1 5 years Cohort III 5 years time

  7. Hta criteria • Do we have enough clarity and consensus in our definitions of the criteria used when health technologies are valued? • Are we smart or wealthy enough to accept a societal perspective (how about the QoL and loss of working capacity)? • Could we avoid the conflict between Hospital perspective and those of Minister of health or Minister of Labor? • How about the patient – tax payer perspective?

  8. Hta and appeal process • Can an non-transparent process offer a real chance for a fair appeal? • How about the patient point of view? • Is this an appeal or a lobby?

  9. FRANCE, OUR OLDER SISTER…

  10. Hta and policy makers • Is the HTA a Sword or an Owl for Policy makers? • We can measure the expenses but how could we assess the morality of a decision? • How could we guarantee the real independence of HTA agency in a time when one main concern of stakeholders from the industry is related to the misuse of HTA ?

  11. Could we accept the mirror? • Is the 3rd payer ready to accept non-official data? • Do all departments from health technology companies sing the same song? • Could we incarcerate the local scientists (usually the best) involved in HTA in order to avoid any external influence?

  12. UNHAPPY / ANGRY / AGGRESSIVE PEOPLES OF HTA What makes them so? Possible solutions?

  13. Possible solutions? Conclusions / reflections • The process should be as transparent as possible • The involvement of different kind of stakeholders (industry, patients, medical doctors…) should be actively promoted • The HTA agency should be as independent as possible (including the financial independence of its members) and not made responsible for the subsequent political decision • It is wise to have clear rules in case of an appeal • and.. Don’t forget to educate the participants!

More Related